Use of camouflage in vitiligo: a cross-sectional survey 

Published in Journal of Cosmetic Dermatology | June 23, 2023 

In a cross-sectional survey, the authors examined the statistics of camouflage use among patients with vitiligo. Results showed that younger patients, female patients, and patients with skin of color were most likely to use camouflage. 

Overall, 45.6% of participants reported using some method of camouflage. One-fourth of nonusers or irregular users cited limited knowledge of products as a barrier to use, and only 21.6% of those under dermatologic care reported that their dermatologist discussed camouflage with them. The authors suggest dermatologists may consider increasing patient education on camouflage, particularly for the demographic groups who are most likely to use it. 

The underestimated role of mitochondria in vitiligo: from oxidative stress to inflammation and cell death 

Published in Experimental Dermatology | June 20, 2023 

In this review article, the authors explore the association between mitochondrial dysfunction and its role in the pathogenesis of vitiligo. They discuss the critical role that nuclear factor erythroid 2-related factor 2 (Nrf2) plays in mitochondrial homeostasis, the possible correlation between downregulation of Nrf2 in vitiligo and mitochondria damage, and why both mitochondria and Nrf2 may be promising targets in vitiligo treatment. 

Vulvar lichen sclerosus and vitiligo: overlap and clinical features 

Published ahead of print in Journal of the American Academy of Dermatology | June 14, 2023 

In this research letter, the authors performed a retrospective case series and systematic review to examine co-occurring cases of vulvar lichen sclerosus (VLS) and vulvar vitiligo (VV). Based on their findings, the authors recommend evaluating patients with VV for key clinical features that may suggest concomitant VLS. 

Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility 

Published ahead of print in American Journal of Human Genetics | June 13, 2023 

In this study, the authors investigated whether predisposing class I major histocompatibility complex (MHC-I) alleles for vitiligo and psoriasis could protect against melanoma. The authors found that autoimmune-allele carriers exhibit a significantly later age of melanoma diagnosis in the Cancer Genome Atlas and a decreased risk of developing melanoma among individuals in the Million Veteran Program.